17147-09-0Relevant academic research and scientific papers
Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi
Martín-Escolano, Rubén,Moreno-Viguri, Elsa,Santivanez-Veliz, Mery,Martin-Montes, Alvaro,Medina-Carmona, Encarnación,Paucar, Rocío,Marín, Clotilde,Azqueta, Amaya,Cirauqui, Nuria,Pey, Angel L.,Pérez-Silanes, Silvia,Sánchez-Moreno, Manuel
, p. 5643 - 5663 (2018/06/20)
Chagas disease is a potentially life-threatening and neglected tropical disease caused by Trypanosoma cruzi. One of the most important challenges related to Chagas disease is the search for new, safe, effective, and affordable drugs since the current ther
Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery
Quiliano, Miguel,Pabón, Adriana,Moles, Ernest,Bonilla-Ramirez, Leonardo,Fabing, Isabelle,Fong, Kim Y.,Nieto-Aco, Diego A.,Wright, David W.,Pizarro, Juan C.,Vettorazzi, Ariane,López de Cerain, Adela,Deharo, Eric,Fernández-Busquets, Xavier,Garavito, Giovanny,Aldana, Ignacio,Galiano, Silvia
, p. 489 - 514 (2018/05/23)
Design, synthesis, structure-activity relationship, cytotoxicity studies, in silico drug-likeness, genotoxicity screening, and in vivo studies of new 1-aryl-3-substituted propanol derivatives led to the identification of nine compounds with promising in vitro (55, 56, 61, 64, 66, and 70–73) and in vivo (66 and 72) antimalarial profiles against Plasmodium falciparum and Plasmodium berghei. Compounds 55, 56, 61, 64, 66 and 70–73 exhibited potent antiplasmodial activity against chloroquine-resistant strain FCR-3 (IC50s 50s 0.7 μM for 3D7, D6, FCR-3 and C235). All of these compounds share appropriate drug-likeness profiles and adequate selectivity indexes (77 SI 184) as well as lack genotoxicity. In vivo efficacy tests in a mouse model showed compounds 66 and 72 to be promising candidates as they exhibited significant parasitemia reductions of 96.4% and 80.4%, respectively. Additional studies such as liver stage and sporogony inhibition, target exploration of heat shock protein 90 of P. falciparum, targeted delivery by immunoliposomes, and enantiomer characterization were performed and strongly reinforce the hypothesis of 1-aryl-3-substituted propanol derivatives as promising antimalarial compounds.
